CTRI/2020/07/026560已完成3 期
Prophylaxis with Neem Capsules (Azadirachta indica) in Healthcare personnel and relatives in Contact with COVID-19 Patients
isarga Biotech Pvt Ltd0 个研究点目标入组 190 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects will be healthcare personnel (physicians, nurses, chemists, pharmacists, stretcher-bearer, administrative and respiratory therapists) who works in healthcare facility or other well characterized high-risk environment. OR Relative of a patient with COVID-19 infection in a participating hospital
- •2.Males and females of 18-60 years of age.
- •3.Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential antivirals.
- •4.Not previously diagnosed with COVID-19.
- •5.Not currently symptomatic with an Acute Respiratory Infection.
- •6.Women of childbearing potential and men who partner with a woman of childbearing potential must agree to use contraceptive methods.
- •7.Ability to swallow and retain oral medication.
- •8.Willingness and ability to comply with trial and follow-up procedures.
- •9.Ability to understand the nature of the trial and give written informed consent.
排除标准
- •1.Known hypersensitivity to neem products.
- •2.Subjects on other prophylactic medications.
- •3.Age <18 years old.
- •4.Suspected or confirmed current COVID-19, defined as: temperature > 38 Celsius; cough; shortness of breath; sore throat; or, if available (not required), positive confirmatory testing for COVID-19.
- •5.Suspected or confirmed convalescent COVID-19, defined as any of the above symptoms within the prior 4 weeks.
- •6.Subjects who is on angiotensin-converting enzyme (ACE) inhibitor.
- •7.Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
- •8.Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
研究者
相似试验
尚未招募
3 期
Effect of Neem {Azadirachta indica A.Juss.} seed kernel powder on dadru kustha (skin disease) .CTRI/2023/03/051046Government Ayurvedic College and Hospital Patna Aryabhatta knowlegdge University Patna Bihar
已完成
3 期
Evaluation of Neem Caplets in the treatment of Acne VulgarisCTRI/2011/06/001806The Himalaya Drug Company50
已完成
3 期
Benefits of neem for Oral lichen planus patients.CTRI/2018/08/015563Dr Ashita Kalaskar60
招募中
2 期
Effect of Nigella Sativa capsules on preparation of endometrium for frozen embryo transfer cyclesDecreased or lack of fertility in a woman of childbearing age.Female infertility, unspecifiedN97.9IRCT20170315033085N5Mashhad University of Medical Sciences116
进行中（未招募）
1 期
One day antiemetic prophylaxis of NEPA (netupitant plus palonosetron) and dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving a combination chemotherapy of doxorubicin or epirubicin with cyclophosphamide (AC-based regimen)Chemotherapy-Induced Nausea and Vomiting (CINV) in breast cancer patients receiving a combination chemotherapy of doxorubicin or epirubicin with cyclophosphamide (AC-based regimen)MedDRA version: 20.0Level: LLTClassification code 10008443Term: Chemotherapy antiemetic prophylaxsisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10008448Term: Chemotherapy induced emesis prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10049091Term: Chemotherapy antiemetic prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10008449Term: Chemotherapy inducted emesis prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10036899Term: Prophylaxis against chemotherapy induced vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2015-003316-20-ITCONSORZIO ONCOTECH150